# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k060359   
B. Purpose for Submission: New device   
C. Measurand: Calibrators and Controls for Insulin assays   
D. Type of Test: Not applicable   
E. Applicant: Denka Seiken Co., LTD.   
F. Proprietary and Established Names: Architect Insulin Calibrators and Controls

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=2 colspan=1>Calibrator,Secondary (JIT)</td><td rowspan=2 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1150,</td><td rowspan=2 colspan=1>75 ClinicalChemistry (CH)</td></tr><tr><td rowspan=1 colspan=1>Calibrator.</td></tr><tr><td rowspan=1 colspan=1>Single(Specified)AnalyteControls(Assayed AndUnassayed)(JJX)</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1660,Quality controlmaterial (assayedand unassayed).</td><td rowspan=1 colspan=1>75 ClinicalChemistry (CH)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

See Indications for use below

2. Indication(s) for use:

# Calibrators

The Architect Insulin Calibrators are for the calibration of the Architect $i$ System when used for the quantitative determination of human insulin in human serum and plasma.

# Controls

The Architect Insulin Controls are for the verification of the accuracy and precision of the Architect $i$ System when used for the quantitative determination of human insulin in human serum or plasma.

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: Architect i System

# I. Device Description:

# Calibrators

The Architect Insulin Calibrators consist of six calibrators (A-F). Calibrator A contains acetate buffer. Calibrators B-F contain insulin in acetate buffer. The calibrators are preserved by sodium azide and other antimicrobial agents. Each Insulin Calibrator kit contains 6 bottles of Calibrators ( $4 . 0 \mathrm { m L }$ fill volume) at the following Insulin concentrations: 0, 3, 10, 100 and $3 0 0 ~ \mathrm { \mu U / m L }$ .

# Controls

The Architect Insulin Controls contain insulin prepared in acetate buffer. The controls are preserved by sodium azide and other antimicrobial agents. Each Insulin Control kit contains 3 bottles of controls (Low, Medium and High) at the following concentrations: 8, 40, and $1 2 0 ~ \mu \mathrm { U / m L }$ .

# J. Substantial Equivalence Information:

Calibrators

<table><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>k021535</td></tr><tr><td rowspan=1 colspan=2>Describe the item being compared</td></tr><tr><td rowspan=1 colspan=2>Bayer ADVIA Centaur and ACS: 180, InsulinCalibrators</td></tr></table>

Controls   

<table><tr><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>k030452</td></tr><tr><td rowspan=1 colspan=2>Describe the item being compared</td></tr><tr><td rowspan=1 colspan=2>Bayer Ligand Plus 1, 2, 3 Controls</td></tr></table>

# Comparison with Predicate

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Calibrator - Similarities</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Calibration ofquantitative assays forhuman insulin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">ChemiluminescentMicroparticleImmunoassay (CMIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Binding ProteinInsulin</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">WHO Insulin 1 stInternational ReferencePreparation 66/304</td><td colspan="1" rowspan="1">bSame</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Calibrator  Differences</td><td colspan="1" rowspan="2">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">Architect i System</td><td colspan="1" rowspan="1">ADVIA Centaur orACS 180</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Acetate buffer withsodium azide andpreservatives</td><td colspan="1" rowspan="1">Buffered saline withcasein, potassiumthiocynate (3.89%),sodium azide andpreservatives</td></tr><tr><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">6 levels: 0, 3, 10, 30and 100 μU/mL</td><td colspan="1" rowspan="1">2 levels: High &amp; Low</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">Item</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Control - Similarities</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Verification of theaccuracy and precision Sameof quantitative assays</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">ChemiluminescentMicroparticleImmunoassay (CMIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">BindingProtein</td><td colspan="1" rowspan="1">Insulin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">Three</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Control - Differences</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">Architect i System</td><td colspan="1" rowspan="1">ADVIA Centaur orACS 180</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Lyophilized</td></tr><tr><td colspan="1" rowspan="1">Type</td><td colspan="1" rowspan="1">Single analyte (insulin)Multiple analytes</td><td colspan="1" rowspan="1">Multiple analytes</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=1 colspan=1>Points to Consider GuidanceDocument on Assayed andUnassayed Quality ControlMaterial; Draft</td><td rowspan=1 colspan=1>OIVD</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/99.html</td></tr><tr><td rowspan=2 colspan=1>Guidance for Industry -Abbreviated 510(k) Submissionsfor In Vitro DiagnosticCalibrators; Final</td><td rowspan=2 colspan=1>OIVD</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/calibrator.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

L. Test Principle: Not applicable

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Not applicable

b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The primary calibrators and controls were manufactured from the WHO Insulin $1 ^ { \mathrm { s t } }$ International Reference Preparation (IRP) 66/304. The Architect Insulin Calibrators and Controls were manufactured by matching to the primary calibrators and controls. Relative light unit (RLU) testing was performed on the Architect i system and RLU values were compared to the corresponding primary calibrators and controls. The sponsor’s acceptance criteria: RLU variation between the Architect Insulin Calibrators and Controls and the primary calibrators and controls must be within $+ / - 1 . 5 \%$ . The sponsor’s studies show that the Architect Calibrators and Controls are stable for 12 months when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ . Protocols and acceptance criteria for stability testing were described and found to be acceptable.

d. Detection limit: Not applicable e. Analytical specificity: Not applicable

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.